Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens

被引:38
作者
Mahon, BE
Hsu, K
Karumuri, S
Kaplan, SL
Mason, EO
Pelton, SI
机构
[1] Boston Univ, Sch Publ Hlth & Med, Dept Epidemiol, Dept Pediat, Boston, MA 02118 USA
[2] Boston Univ, Sect Pediat Infect Dis, Boston, MA 02215 USA
[3] Massachusetts Dept Publ Hlth, Bur Communicable Dis Control, Div Epidemiol & Immunizat, Jamaica Plain, MA USA
[4] Baylor Coll Med, Dept Pediat, Sect Pediat Infect Dis, Houston, TX 77030 USA
关键词
pneumococcal infections; pneumococcal vaccines; children; United States; vaccination;
D O I
10.1016/j.vaccine.2005.12.025
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
We estimated the effectiveness of abbreviated regimens of 7-valent pneumococcal conjugate vaccine (PCV7) based on serotyped cases of invasive pneumococcal disease (IPD) in children under 5 reported from 2001 to 2004 to two US surveillance programs. Vaccination regimens included in the analysis were I dose < 3 months old, 2 doses < 5 months old, 3 doses < 7 months old, full schedule (3 doses and a booster), I dose at 12-23 months, and 2 doses at 12-23 months. Vaccine effectiveness (VE) was calculated as (1 - Mantel-Haenszel summary odds ratio in vaccinated children, as compared to unvaccinated children) x 100% for each regimen, stratifying by year. Among 400 eligible cases, for vaccine-type IPD, VE was 90.5% for the full schedule, 76.6% for 3 doses < 7 months old, and 70.5% for 2 doses < 5 months old; 1 dose < 3 months provided no significant protection. No regimen provided significant protection against vaccine-related serotypes. Data for regimens begun at 12-23 months were inconclusive. These data support the use of the 2-dose and 3-dose infant PCV7 regimens when the full series cannot be delivered and detail the limitations of abbreviated dosing regimens. (c) 2005 Elsevier Ltd. All rights reserved.
引用
收藏
页码:2514 / 2520
页数:7
相关论文
共 32 条
[1]  
Abramson JS, 2000, PEDIATRICS, V106, P362
[2]  
[Anonymous], 2000, MMWR Recomm Rep, V49, P1
[3]  
[Anonymous], 2005, MMWR Morb Mortal Wkly Rep
[4]   Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children [J].
Black, S ;
Shinefield, H ;
Fireman, B ;
Lewis, E ;
Ray, P ;
Hansen, JR ;
Elvin, L ;
Ensor, KM ;
Hackell, J ;
Siber, G ;
Malinoski, F ;
Madore, D ;
Chang, I ;
Kohberger, R ;
Watson, W ;
Austrian, R ;
Edwards, K .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2000, 19 (03) :187-195
[5]   PNEUMOCOCCAL VACCINE EFFICACY IN SELECTED POPULATIONS IN THE UNITED-STATES [J].
BOLAN, G ;
BROOME, CV ;
FACKLAM, RR ;
PLIKAYTIS, BD ;
FRASER, DW ;
SCHLECH, WF .
ANNALS OF INTERNAL MEDICINE, 1986, 104 (01) :1-6
[6]   Who's calling the shots? Pediatricians' adherence to the 2001-2003 pneumococcal conjugate vaccine-shortage recommendations [J].
Broder, KR ;
MacNeil, A ;
Malone, S ;
Schwartz, B ;
Baughman, AL ;
Murphy, TV ;
Pickering, LK ;
Moran, JS .
PEDIATRICS, 2005, 115 (06) :1479-1487
[7]   PNEUMOCOCCAL DISEASE AFTER PNEUMOCOCCAL VACCINATION - AN ALTERNATIVE METHOD TO ESTIMATE THE EFFICACY OF PNEUMOCOCCAL VACCINE [J].
BROOME, CV ;
FACKLAM, RR ;
FRASER, DW .
NEW ENGLAND JOURNAL OF MEDICINE, 1980, 303 (10) :549-552
[8]  
BUTLER J, 2004, PRECARIOUS LIFE, P148
[9]   PNEUMOCOCCAL POLYSACCHARIDE VACCINE EFFICACY - AN EVALUATION OF CURRENT RECOMMENDATIONS [J].
BUTLER, JC ;
BREIMAN, RF ;
CAMPBELL, JF ;
LIPMAN, HB ;
BROOME, CV ;
FACKLAM, RR .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (15) :1826-1831
[10]   SEROTYPE DISTRIBUTION OF STREPTOCOCCUS-PNEUMONIAE INFECTIONS AMONG PRESCHOOL-CHILDREN IN THE UNITED-STATES, 1978-1994 - IMPLICATIONS FOR DEVELOPMENT OF A CONJUGATE VACCINE [J].
BUTLER, JC ;
BREIMAN, RF ;
LIPMAN, HB ;
HOFMANN, J ;
FACKLAM, RR .
JOURNAL OF INFECTIOUS DISEASES, 1995, 171 (04) :885-889